Posters

2023
ACoP14, National Harbor, MD, US
fIVE DB Calculator: web application for parameter calculation from in vitro data
Authors: Alexander Stepanov, Oleg Demin
Modeling of the effects of IFNγ and TNFα release on pharmacokinetics of a bispecific antibody against PD1 and CD40
Authors: Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Calculation of PD-L1 dissociation constant using available gel filtration experimental data
Authors: Ekaterina Goryacheva, Oleg Demin
fIVE DB as a tool to collect data from in vitro experiments and automatically calculate kinetic parameters: focus on impact of experimental conditions
Authors: Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
Secure and scalable computational environment for QSP modeling and simulations
Authors: Ivan Borisov, Evgeny Metelkin
Analytical approaches to optimize structure and reduce complexity of QSP models: focus on immuno-oncology
Authors: Maria Mironovich, Julia Sergienko, Oleg Demin
QSP modeling efficacy of nilotinib on pathologic proteins in Parkinson’s disease
Authors: Tatiana Karelina, Olga Ivanova, Oleg Demin
Development and Validation of a QSP Model of Synovial Sarcoma Treatment with Lete-cel: Implementation of ORR and PFS
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Dmitry Shchelokov (1), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Translational PK/RO model of tetravalent bispecific antibody CTX8371: effect of bispecific binding and multimeric complexes formation on the PD1 and PDL1 receptor occupancy
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
QSP model of neutrophils depletion during Sarilumab treatment constructed from Immune Response Template submodels
Authors: Veronika Musatova, Oleg Demin, Anna Viktorenko
SITC 2023, San Diego, CA, US
Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data
Authors: Oleg Demin (2), Sergey Smirnov (1), Alexandra Diakonova (1), Anna Roskoshnaya (1), Gaurav Bajaj (3), Homer Adams III (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro N
Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling
Authors: Oleg Demin Jr, Dmitry Shchelokov
A Quantitative Systems Pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies
Authors: Alexandra Diakonova (1), Sergey Smirnov (1), Anna Roskoshnaia (1), Ivan Borisov (1), Oleg Demin (2), Gaurav Bajaj (3), Homer Adams III (3), Maria Jure-Kunkel (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, N
Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies via mathematical modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Natalia Ramos Hernandez (3), Thomas Faitg (3), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
14th Annual World Bispecific Summit, Boston, MA
Mechanistic Translational PK/RO Modeling vs MABEL to Predict First-in-Human Dose for Bispecific & Multispecific Antibodies
Authors: Oleg Demin Jr
Speaker: Oleg Demin
PAGE 2023, A Coruna, Spain
An algorithm to generate virtual patients cohort for a model of solid tumor treatment
Authors: Ivan Borisov, Evgeny Metelkin, Galina Kolesova, Oleg Demin
2022
ACoP13, Aurora, Colorado, US
Pharmacokinetics modeling and optimal dose prediction for a bispecific antibody against CD40 and PD1
Authors: Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
The QSP model of microglia role in tau pathology and neurodegeneration
Authors: Stepan Lerner, Maria Myshkina, Tatiana Karelina
Estimation of Imax and IC50 for PD1-PDL1 inhibition of T cell proliferation
Authors: Oleg Demin
Methodological aspects of rate law derivation of cell dynamics processes: focus on QSP model development
Authors: Oleg Demin, Maria Mironovich, Julia Sergienko
Quantitative systems pharmacology modeling of immune response role in Parkinson’s disease
Authors: Tatiana Karelina, Olga Ivanova, Oleg Demin
Quantitative systems pharmacology model for neurofilament L dynamics in multiple sclerosis and under immunomodulatory therapies
Authors: Polina Pchelintseva, Anna Mishina, Tatiana Karelina
Virtual Patients Parallel Simulations in a Hybrid Cloud Environment
Authors: Ivan Borisov, Evgeny Metelkin, Tatiana Karelina, Oleg Demin
ECTRIMS 2022, Amsterdam, the Netherlands and Online
Neurodegeneration quantitative systems pharmacology modeling for analysis of multiple sclerosis therapy
Authors: Polina Pchelintseva (1), Anna Mishina (1), Tatiana Karelina (2)
Affiliation: (1) InSysBio, Moscow, Russia; (2) InSysBio CY, Paphos, Cyprus